| Literature DB >> 29303958 |
Qin Zhang1, Chengcheng Song2, Jun Zhao3,4, Xiaomei Shi5, Meiling Sun6, Jing Liu7, Yinghuan Fu8,9, Wengang Jin10, Beiwei Zhu11.
Abstract
The gonad of jellyfish (RhopilemaesculentumKishinouye), containing high protein content with a rich amino acid composition, is suitable for the preparation of bioactive peptides. Jellyfish gonad was hydrolysed with neutral protease to obtain jellyfish gonad protein hydrolysate (JGPH), which was then purified sequentially by ultrafiltration, gel filtration chromatography, and RP-HPLC. The peptides were characterized with HPLC-MS/MS. One peptide with amino acid sequence Ser-Tyr (SY) was identified and synthesized, which showed good ACE inhibitory and antioxidant activity. The IC50 of this peptide on DPPH, ·OH, super oxygen anion scavenging activities, and ACE inhibitory activity are 84.623 μM, 1177.632 μM, 456.663 μM, and 1164.179 μM, respectively. The anchor in the binding site of SY and ACE C-domain (ACE-C) was obtained by molecular simulations. The results showed that the dipeptide purified from jellyfish gonad protein hydrolysates can be used as functional food material and is helpful in the study of antioxidant and inhibition of ACE.Entities:
Keywords: ACE inhibitory activity; antioxidant activity; jellyfish gonad protein hydrolysate; peptides
Mesh:
Substances:
Year: 2018 PMID: 29303958 PMCID: PMC6017638 DOI: 10.3390/molecules23010094
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Amino acid composition of JGPH (-P1, -P2, -P3).
| Types of Amino Acids | JGPH-P1(g/100 g) | JGPH-P2(g/100 g) | JGPH-P3(g/100 g) |
|---|---|---|---|
| Asp | 4.43 ± 0.02 b | 4.77 ± 0.33 b | 3.68 ± 0.06 a |
| Glu | 5.96 ± 0.06 b | 6.20 ± 0.20 b | 4.51 ± 0.18 a |
| Ser | 2.20 ± 0.07 a | 2.18 ± 0.19 a | 1.91 ± 0.05 a |
| Arg | 2.79 ± 0.03 ab | 3.20 ± 0.26 b | 2.66 ± 0.03 a |
| Gly | 4.83 ± 0.23 a | 4.50 ± 0.22 a | 4.34 ± 0.16 a |
| Thr A | 2.60 ± 0.26 a | 2.26 ± 0.26 a | 1.91 ± 0.20 a |
| Pro C | 2.06 ± 0.03 b | 1.72 ± 0.12 a | 1.52 ± 0.03 a |
| Ala C | 2.67 ± 0.09 a | 2.95 ± 0.04 a | 2.74 ± 0.17 a |
| Val AC | 2.63 ± 0.01 b | 2.76 ± 0.07 c | 2.44 ± 0.02 a |
| Met AC | 0.85 ± 0.00 a | 0.99 ± 0.02 b | 1.01 ± 0.03 b |
| Cys | 0.22 ± 0.01 | 0.03 ± 0.01 | — |
| Ile AC | 2.01 ± 0.01 a | 2.12 ± 0.27 a | 1.99 ± 0.07 a |
| Leu AC | 3.00 ± 0.26 a | 3.42 ± 0.06 a | 3.45 ± 0.02 a |
| Trp ABC | 3.22 ± 0.16 a | 3.48 ± 0.13 a | 4.01 ± 0.03 b |
| Phe ABC | 0.06 ± 0.01 a | 0.05 ± 0.01 a | 0.06 ± 0.01 a |
| His | 4.95 ± 0.58 a | 4.39 ± 0.20 a | 4.23 ± 0.51 a |
| Lys A | 5.91 ± 0.11 b | 6.25 ± 0.04 c | 4.92 ± 0.12 a |
| Tyr B | 1.55 ± 0.07 a | 1.69 ± 0.29 a | 4.01 ± 0.03 a |
| total | 51.93 ± 2.02 b | 52.97 ± 2.72 b | 47.40 ± 1.75 a |
Note: the uppercase letter A stands for the human body essential amino acids; the uppercase letter B stands for aromatic amino acids; the uppercase letter C stands for hydrophobic amino acids. Data are presented as means ± SD (n = 3), different letters (a–c) indicate statistical different kinds of amino acid content differences among three components (p < 0.05).
DPPH radical scavenging activity and ACE inhibitory activity of JGPH (-P1, -P2, -P3).
| Components | DPPH Scavenging Activity (%) 1 | ACE Inhibition Activity (%) 2 |
|---|---|---|
| JGPH-P1 | 39.87 A | 79.91 a |
| JGPH-P2 | 65.68 B | 79.98 b |
| JGPH-P3 | 87.35 C | 87.35 c |
Note: 1 The concentration of sample was 2.5 mg/mL. 2 The concentration of sample was 2.0 mg/mL. Data are presented as means ± SD (n = 3), significant difference of DPPH scavenging activity is marked with different uppercase letters (A–C) (p < 0.05), significant difference of ACE inhibitory activity is marked with different lowercase letters (a–c) (p < 0.05).
Figure 1Elution profile of JGPH-P3 using a Sephadex G-25 column. A–F were six major parts by the Sephadex G-25 gel column.
Figure 2ACE inhibitory activities of JGPH-P3 A–F.
IC50 values of JGPH-P3 A–F.
| Fractions | IC50 of DPPH Scavenging Activity (mg/mL) | IC50 of ACE Inhibitory Activity (mg/mL) |
|---|---|---|
| JGPH-P3A | 0.62 ± 0.0071 D | 1.01 ± 0.0379 b |
| JGPH-P3B | 0.95 ± 0.0314 E | 1.07 ± 0.0376 b |
| JGPH-P3C | 1.56 ± 0.0206 F | 1.67 ± 0.0412 c |
| JGPH-P3D | 0.48 ± 0.0005 C | 0.96 ± 0.0197 b |
| JGPH-P3E | 0.29 ± 0.0084 A | 4.38 ± 0.0154 d |
| JGPH-P3F | 0.38 ± 0.0095 B | 0.54 ± 0.0241 a |
Note: Data are presented as means ± SD (n = 3), significant difference of DPPH scavenging activity (IC50) is marked with different uppercase letters (A–F) (p < 0.05), significant difference of ACE inhibitory activity (IC50) is marked with different lowercase letters (a–d) (p < 0.05).
Figure 3DPPH radical scavenging activity of JGPH-P3 A–F.
Figure 4ESI-MS/MS chromatography of P3D5.
Figure 5(a) DPPH radical scavenging activity of Ser-Tyr. (b) Hydroxyl radical scavenging activity of Ser-Tyr. (c) Superoxide anion radical scavenging activity of Ser-Tyr. (d) ACE inhibitory activity of Ser-Tyr.
IC50 values of the Ser-Tyr.
| Bioactivities | IC50 (μM) |
|---|---|
| ACE inhibitory | 1164.179 ± 0.37 |
| DPPH radical | 84.623 ± 0.75 |
| GSH (DPPH radical) | 162.695 ± 0.32 |
| Hydroxyl radical | 1177.632 ± 1.86 |
| GSH (hydroxyl radical) | 7306.616 ± 0.32 |
| Superoxide radical | 456.663 ± 2.23 |
Figure 6Lineweaver–Burk plots on ACE inhibitory activity of Ser-Tyr.
Figure 7The docking of Ser-Tyr binding with the human ACE-C.